Hirotsugu Atarashi

3 weeks ago | onlinelibrary.wiley.com | Eitaro Kodani |Takeshi Yamashita |Hiroshi Inoue |Hirotsugu Atarashi

1 The Authors' Reply We would like to thank Dr. Hassan for your interest in our recently published study “Association between changes in heart rate and adverse events in patients with non-valvular atrial fibrillation: A post hoc analysis of the J-RHYTHM Registry.” [1] There were several limitations in our study as already mentioned in the article [1]. Our replies to the comments are as follows. First, we agree that heart rate (HR) fluctuation may have influenced the incidence of adverse events.

Aug 1, 2023 | jacc.org | Yukihiro Koretsune |Takeshi Yamashita |Masaharu Akao |Hirotsugu Atarashi

IntroductionAtrial fibrillation (AF) is associated with an increased risk of stroke and systemic embolic events (SEE).

Jun 1, 2023 | jacc.org | Wataru Shimizu |Takeshi Yamashita |Masaharu Akao |Hirotsugu Atarashi

JACC Journals › JACC: Asia › Archives › Vol. 3 No. 3_Part_2 AbstractBackgroundAdvancing age, decreasing renal function, and atrial fibrillation are strongly associated. Real-world evidence of direct oral anticoagulant (DOAC) use among elderly patients ≥75 years of age with nonvalvular atrial fibrillation and renal dysfunction is limited. ObjectivesThis study sought to assess 2-year outcomes and anticoagulant treatment, stratified by renal function.